期刊文献+

人呼吸道合胞病毒RNA聚合酶复合体蛋白N、P、L和M2-1重组质粒的构建和鉴定 被引量:1

Construction and identified of N,P,L and M2-1 of human respiratory syncytial virus RNA polymerase complex
下载PDF
导出
摘要 目的构建可表达人呼吸道合胞病毒(RSV)转录延长/终止抑制因子M2-1(简称M2-1)、核蛋白(N)、磷蛋白(P)和大蛋白(L)的真核表达载体并鉴定蛋白表达情况。方法采用合成T7启动子Oligo DNA及PCR方法获得含有T7启动子的表达盒,通过体外连接方法克隆入载体px8δT,制备表达载体px8δT-PT。设计3对PCR引物,PCR扩增出RSV的M2-1、N和P基因,并克隆至px8δT-PT,构建px8δT-PT-M2-1、px8δT-PT-N和px8δT-PT-P。同时利用已有的质粒pcDNA3.1-L构建px8δT-PT-L。用重组质粒转染BSR T7/5细胞,72 h后再用Western blot法鉴定蛋白的表达。结果成功实现px8δT的改造,构建的4种重组质粒px8δT-PT-M2-1、px8δT-PT-N、px8δT-PT-P和px8δT-PT-L,经限制性内切酶分析与预期一致,经Western blot法分析证实M2-1、N及P蛋白被表达。结论获得以T7为启动子的表达载体px8δT-P,成功构建了含有M2-1、N及P编码基因的表达载体,为利用反向遗传学技术进一步改造RSV奠定了基础。 Objective To construct and identify the eukaryotic expression vector encoding human respiratory syncytial virus(RSV) transcription elongation/antitermination factor M2-1(M2-1),nucleoprotein(N),phosphoprotein(P) and large protein(L).Methods Three pairs of PCR primers were designed to amplify M2-1,N and P genes.The PCR products were cloned into expression vector of px8δT-PT,which was controlled by T7 promoter to construct recombinant plasmids of px8δT-PT-M2-1,px8δT-PT-N and px8δT-PT-P.Meanwhile,px8δT-PT-L was constructed from pcDNA3.1-L.The resultant recombinant plasmids were transfected into BSR T7/5 cells and transgene expression was identified by Western blot at 72 h after transfection.Results By restriction endonuclease analysis,four plasmids encoding N,P,L and M2-1 were constructed successfully,and the expression of three genes of N,P,and M2-1 was confirmed by Western blot.Conclusion The T7 promoter-based expression vector encoding M2-1,N and P genes,respectively,are successfully constructed,which are competented for modifying RSV genetically by reverse genetics technique.
出处 《安徽医科大学学报》 CAS 北大核心 2012年第8期895-899,共5页 Acta Universitatis Medicinalis Anhui
关键词 人呼吸道合胞病毒 核蛋白 磷蛋白 转录延长/终止抑制因子M2-1 大蛋白 human respiratory syncytial virus; nucleoprotein; phosphoprotein; transcription elongation/antitermination factor M2-1; large protein
  • 相关文献

参考文献14

  • 1Castagne N, Barbier A, Bernard J, et al. Biochemical character-ization of the respiratory syncytial virus P-P and P-N priotein com- plexs and localization of the P protein oligomerization domain [ J ]. J Gen Virol, 2004, 85(Pt 6) :1643 -53.
  • 2Lu B, Ma C H, Brazas R, et al. The major phosphorylation sites of the respiratory syncytial virus phosphoprotein are dispensable for virus replication in vitro [ J ]. J Virol, 2002,76 (21) :10776 -84.
  • 3Sunters A, Mattos S F, Stahl M, et al. FoxO3a transcriptional reg- ulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines[ J ]. J Biol Chem, 2003,278 (50) :49795 - 805.
  • 4何金生,付远辉,洪涛.人呼吸道合胞病毒活疫苗研究进展[J].中国科学:生命科学,2011,41(1):1-12. 被引量:14
  • 5Karron R A. Respiratory syncytial virus vaccine [ M ]//5th ed. Plotkin S A, Orenstein W A, Offit P A. Vaccines. Philadelphia: Sauaders Elsevier, 2008 : 1283 - 93.
  • 6Whitehead S S, Firestone C Y, Karron R A, et al. Addition of a missense mutation present in the L gene of respiratory syncytial vi- rus (RSV)cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity [ J ]. J Virol, 1999, 73(2) : 871 -7.
  • 7Krempl C, Murphy B R, Collins P L. Recombinant respiratory syncytial virus with the G and F genes shifted to the promoter-prox- imal positions[J]. J Virol, 2002, 76(23) : 11931 -42.
  • 8付远辉,何金生,洪涛.反向遗传学在呼吸道合胞病毒减毒活疫苗研究中的应用[J].中国生物工程杂志,2011,31(3):97-100. 被引量:4
  • 9Malykhina O, Yednak M A, Collins P L, et al. A respiratory syn- cytial virus replicon that foreign gene expression is noncytotoxic and capable of long-term[ J]. J Virol, 2011, 85 (10) :4792 - 801.
  • 10Wright P F, Karron R A, Belshe R B, et al. The absence of en- hanced disease with wild type respiratory syncytial virus infectiong occurring after receipt of live, attenuated, respiratour syncytial vi- res vaccineds[J]. Vaccine, 2007,25(42) :7372 -8.

二级参考文献111

  • 1Fleming D M, Elliot A J. Respiratory syncytial virus: a sleeping giant? Eur Respir J, 2007, 30:1029-1031.
  • 2Karron R A. Respiratory Syncytial Virus Vaccine. In: Plotkin S A, Orenstein W A, Offit P A, eds. Vaccines, 5th ed. Philadelphia: Saunders, Elsevier, 2008. 1283-1293.
  • 3Power U F. Respiratory syncytial virus (RSV) vaccines-two steps back for one leap forward. J Clin Virol, 2008, 41:38-44.
  • 4Englund J. In search of a vaccine for respiratory syncytial virus: the saga continues. J Infect Dis, 2005, 191:1036-1039.
  • 5Zeng R, Qi X, Gong W, et al. Long-lasting balanced immunity and protective efficacy against respiratory syncytial virus in mice induced by a recombinant protein G1F/M2. Vaccine, 2007, 25:7422-7428.
  • 6Fu Y, He J, Zheng X, et al. Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice. Biochem Biophys Res Commun, 2009, 381:528-532.
  • 7Fu Y H, He J S, Wang X B, et al. A prime-boost vaccination strategy using attenuated Salmonella typhimurium and a replication-deficient recombinant adenovirus vector elicits protective immunity against human respiratory syncytial virus. Biochem Bioph Res Co, 2010, 395: 87-92.
  • 8Xie C, He J S, Zhang M, et al. Oral respiratory syncytial virus (RSV) DNA vaccine expressing RSV F protein delivered by attenuated Salmonella typhimurium. Hum Gene Ther, 2007, 18:746-752.
  • 9Ghildyal R, Ho A, Jarls D A. Central role of the respiratory syncytial virus matrix protein in infection. FEMS Microbiol Rev, 2006, 30" 692-705.
  • 10Brandenburg A H, Neijens H J, Osterhaus A D. Pathogenesis of RSV lower respiratory tract infection: implications for vaccine development. Vaccine, 2001, 19:2769-2782.

共引文献15

同被引文献1

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部